Studies have reported a significant reduction in the risk of ischemic heart disease (IHD) in patients treated with 5-aminosalicylates, and a modest risk reduction in those receiving azathioprine or anti-TNF therapy [44]. The gene discussed is TNF; the disease is coronary artery disorder.